Whitehawk Therapeutics (WHWK) Debt to Equity (2020 - 2021)
Whitehawk Therapeutics (WHWK) reported Debt to Equity of $0.04 for Q4 2021, up 103.83% year-over-year from $0.02 in Q4 2020, and up 15.16% on a QoQ basis from $0.04 in Q3 2021.
Whitehawk Therapeutics (WHWK) has 2 years of Debt to Equity data on file, last reported at $0.04 in Q4 2021.
- Quarterly Debt to Equity rose 103.83% year-over-year to $0.04 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $0.04 (up 103.83% YoY) and the FY2021 annual result came in at $0.04, up 103.83% from the prior year.
- Debt to Equity rose to $0.04 in Q4 2021 per WHWK's latest filing, from $0.04 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.04 in Q4 2021 and bottomed at -$1.15 in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.06 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Whitehawk Therapeutics | 312.26 Mn | 189.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 0.04 |
| Sep 30, 2021 | 0.04 |
| Dec 31, 2020 | -1.15 |